Evidence map›Paper›PMID 40591095›Full record

ReviewCurrent neurology and neuroscience reports2025

Cerebrovascular and Peripheral Vascular Complications in Cancer Patients.

Julien Rousseau, Patrick Y Wen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Smart assistive technologies for neurodisorders: A review on AI, IoT, and wearable systems for enhanced patient care.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Julien RousseauCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. julien_rousseau@dfci.harvard.edu.ORCID http://orcid.org/0000-0003-1889-018X
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of this reviewThis review explores the complex relationship between cancer and vascular disease. It aims to synthesize current evidence on the epidemiology, mechanisms, management, and outcomes of ischemic stroke, cerebral venous sinus thrombosis (CVST), venous thromboembolism (VTE) in brain tumor patients, and intracranial hemorrhage (ICH), while highlighting the cerebrovascular risks of systemic cancer therapies. RECENT

findingsRecent studies reveal that cancer patients are at increased risk for ischemic stroke, often from cancer-specific mechanisms such as hypercoagulability, non-bacterial thrombotic endocarditis, and tumor embolism. VTE is increasingly recognized in patients with primary brain tumors. Emerging data support the safety of direct oral anticoagulants over low-molecular weight heparin in selected patients with brain tumors. Cancer treatments-including immune checkpoint inhibitors (ICIs), hormonal therapies, and radiation-contribute to cerebrovascular risk. Vascular complications are underrecognized yet significant contributors to morbidity and mortality in cancer patients. Multidisciplinary strategies, personalized risk stratification, and targeted research are critical to improving outcomes in this vulnerable population.

Indexed as

Brain NeoplasmsCerebrovascular DisordersIntracranial HemorrhagesIschemic StrokeNeoplasmsSinus Thrombosis, IntracranialVenous ThromboembolismHumansCancer-associated strokeCancer-related thrombosisCerebral venous sinus thrombosisIntracranial hemorrhageVenous thromboembolism

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.